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As older patients are eligible for allogeneic hematopoietic cell transplantation (HCT), older siblings are
increasingly proposed as donors. We studied the impact of donor age on the tempo of hematopoietic
engraftment and donor chimerism, acute and chronic graft-versus-host disease (GVHD), and nonrelapse
mortality (NRM) among 1174 consecutive patients undergoing myeloablative and 367 patients undergoing
nonmyeloablative HCT from HLA-matched related or unrelated donors with granulocyte colonyestimulating
factoremobilized peripheral blood mononuclear cell allografts. Sustained engraftment rates were 97% and
98% in patients undergoing myeloablative and nonmyeloablative conditioning, respectively, for grafts from
donors < 60 years old (younger; n ¼ 1416) and 98% and 100%, respectively, for those from donors 60 years
old (older; n ¼ 125). No signiﬁcant differences were seen in the tempo of neutrophil and platelet recoveries
and donor chimerism except for an average 1.3-day delay in neutrophil recovery among myeloablative pa-
tients with older donors (P ¼ .04). CD34þ cell dose had an independent effect on the tempo of engraftment.
Aged stem cells did not convey an increased risk of donor-derived clonal disorders after HCT. Myeloablative
and nonmyeloablative recipients with older sibling donors had signiﬁcantly less grade II to IV acute GVHD
than recipients with grafts from younger unrelated donors. Rates of grade III and IV acute GVHD, chronic
GVHD, and NRM for recipients with older donors were not signiﬁcantly different from recipients with
younger donors. In conclusion, grafts from donors 60 years old do not adversely affect outcomes of
allogeneic HCT compared with grafts from younger donors.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION conclusions of these studies, however, could be partly caused
With reductions in the intensity of conditioning regimens
and improvements in supportive care, older patients have
increasingly become eligible for allogeneic hematopoietic cell
transplantation (HCT) [1,2]. As the age of allogeneic HCT re-
cipients has increased, the ageof sibling donors has increased,
as well. The impact of patient age and medical comorbidities
on transplantation outcome has been explored extensively
[3-6]. However, the impact of increasing donor age on the
functional ﬁtness of hematopoietic cells has been controver-
sial [7-16]. Most of the work on stem cell aging has been
conducted inmice. As deHaan et al. observed, “the discrepantdgments on page 111.
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ty for Blood and Marrow Transplantation.by differences in mouse strains used, because strain-
dependent increases or decreases in primitive hematopoiet-
ic cell frequency and function have been reported” [17]. Also,
the longevity of hematopoietic stem cells makes them ideal
targets for mutagenic changes, which raises the theoretical
concern that recipients of aged stem cells are at an increased
risk of developing malignant clonal disorders [15]. The
uncertainties raised both by these theoretical considerations
and the preclinical work prompted the current clinical report.
In allogeneic HCT for treatment of human blood disorders, a
relatively small inoculum of donor hematopoietic cells is
called upon to recapitulate a diverse and fully functional
hematopoietic system in the recipient. In earlier reports, we
described polyclonal normal hematopoiesis and normal or
near-normal immune function in younger patients (3 to
40 years old at the time of HCT)whohad younger donors (4 to
50 years old) and were studied 20 to 30 years after trans-
plantation [18,19]. The ﬁrst questions posed by the current
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cells impaired their ability to repopulate the recipient he-
matopoietic niche, resulting in a delay of neutrophil and
platelet recoveries, andwhether aged stemcells increased the
risk of post-transplantation clonal disorders. Another ques-
tionwas whether grafts from older donors adversely affected
long-term transplantation-related outcomes apart from
relapse of the underlying disease. To obtain the answers, we
useddata fromasingle center and studied the impactof donor
age on the tempo of hematopoietic engraftment, the devel-
opment of clonal disorders and acute and chronic graft-
versus-host disease (GVHD), and on the 5-year nonrelapse
mortality (NRM) after allogeneic HCT among 1541 patients,
the majority of whom had hematologic malignancies.
PATIENTS AND METHODS
The decision to analyze patients given myeloablative conditioning and
nonmyeloablative conditioning separately was based on several consider-
ations: (1) the greater degree of marrow ablation with the former
compared with the latter regimen imposes greater immediate replicative
demands on the donor hematopoietic cells; (2) the incidence of acute
GVHD at our center is historically higher among myeloablative compared
with nonmyeloablative recipients [20]; and (3) as a rule, patients given
nonmyeloablative conditioning at our center are either 55 to 65 years oldTable 1
Characteristics of Recipients of Allogeneic Hematopoietic Cell Transplantation afte
Characteristic Related Donor <60 yr (n ¼ 545)
Patient age, yr
<50 361 (66)*
50 184 (34)
Patient sex
Female 235 (43)
Male 310 (57)
Ideal body weight
Data available, n 488
Median (range), kg 66 (7-119)
Donor
Related 545 (100)
Unrelated 0
Recipient/donor CMV status
e/e 179 (33)
e/þ 75 (14)
þ/e 105 (19)
þ/þ 183 (34)
Missing
Received TBI
No 324 (59)y
Yes 221 (41)
CD34þ cell dose/kg  106
Data available, n 512
Median (range) 7.5 (2.1-31.5)*
TNC cell dose/kg  108
Data available, n 512
Median (range) 11.6 (3.4-43.0)*
Transplantation yr
1999-2000 105 (19)
2001-2002 114 (21)
2003-2005 188 (35)
2006-2009 138 (25)
Diagnosis
AML 210 (39)
MDS 137 (25)y
CML 70 (13)y
ALL 63 (12)y
CLL/HL/NHL 46 (8)
Other 19 (3)
Median follow-up, mo 50
CMV indicates cytomegalovirus; TNC, total nucleated cells; AML, acute myeloid le
ALL, acute lymphocytic leukemia; CLL, chronic lymphocytic leukemia; HL, Hodgkin
Data presented are n (%) unless otherwise indicated.
y P < .05 versus older donor group.
* P < .001 versus older donor group.or, if younger, have medical comorbidities that preclude myeloablative
conditioning.
Patients
Myeloablative conditioning
We retrieved data for all patients receiving myeloablative conditioning
and granulocyte colonyestimulating factoremobilized peripheral blood
mononuclear cell (G-PBMC)ederived allografts from an HLA-matched
related or unrelated donor for any diagnosis at Fred Hutchinson Cancer
Research Center between January 1, 1999 and December 31, 2009 (n¼ 1174).
Characteristics of patients undergoing myeloablative allogeneic HCT during
the study period are given in Table 1. Patients had HLA-identical sibling
donors (n ¼ 604, 51%) or HLA-matched unrelated donors (n ¼ 570, 49%).
Ninety-six percent of related older donors had 2 days of G-PBMC collections,
where 4% had more than 2 collections. Forty-two percent of patients were
conditioned with total body irradiation (TBI)ebased regimens, whereas the
remaining 58% received chemotherapy-only conditioning. Most donors
(95%) were younger than 60 years of age, whereas 60 (5%) of donors were 60
or older at the time of hematopoietic cell collection. The majority of re-
cipients of grafts from older donors were 50 years or older, whereas most of
the recipients of grafts from younger donors were less than 50 years old.
Nonmyeloablative conditioning
We also retrieved data on all patients receiving allogeneic HCT with a G-
PBMCederived graft on prospective trials registered with ClinicalTrials.gov
for any diagnosis after nonmyeloablative conditioning, which we deﬁned as
2 Gy TBI with or without ﬂudarabine 90 mg/m2 as reported previouslyr Myeloablative Conditioning
Unrelated Donor <60 yr (n ¼ 569) Donor 60 yr (n ¼ 60)
355 (62)* 5 (8)
214 (38) 55 (92)
258 (45) 21 (35)
311 (55) 39 (65)
515 55
66 (7-173) 68 (50-85)
0 59 (98)
569 (100) 1 (2)
194 (34) 20 (34)
57 (10) 6 (10)
199 (35) 14 (24)
119 (21) 19 (32)
310 (54)y 44 (73)
259 (46) 16 (27)
513 55
7.9 (.7-57.9)* 5.7 (2.1-17.4)
513 55
10.5 (2.0-46.7)* 14.7 (5.9-45.0)
34 (6) 7 (12)
132 (23) 9 (15)
235 (41) 22 (37)
168 (30) 22 (37)
242 (43) 24 (40)
166 (29)y 28 (47)
38 (7) 4 (7)
93 (16)y 1 (2)
19 (3) 2 (3)
11 (2) 1 (2)
49 43
ukemia; MDS, myelodysplastic syndrome; CML, chronic myeloid leukemia;
lymphoma; NHL, non-Hodgkin lymphoma.
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except that a single allele-level mismatch at an HLA-class I or class II locus
was allowed. Table 2 shows the characteristics of 367 patients receiving G-
PBMC allografts after conditioning with 2 Gy TBI with or without ﬂudar-
abine 90 mg/m2. Sixty-ﬁve patients (18%) had donors aged 60 years, all of
whom were siblings. The oldest donor was 83 years of age. Among patients
with donors younger than 60 years, the majority (198, 66%) had unrelated
donors. Eighty-eight percent of older donors had a standard 2-day G-PBMC
collection, whereas 12% had a third day of collection.
Engraftment
Day of neutrophil engraftment was deﬁned as the ﬁrst day on which a
patient reached an absolute neutrophil count  500 cells/mL for at least 3
consecutive days. Day of platelet engraftment was deﬁned as the ﬁrst day on
which a patient reached a platelet count 20,000 cells/mL for at least 7
consecutive days without transfusion support.
GVHD and NRM
For the GVHD and NRM analyses, patients were divided into 3 groups,
those with HLA-matched related donors <60 years old, those with HLA-
matched unrelated donors <60 years old, and those with HLA-matched
related donors 60 years old.
Acute and chronicGVHDweregraded as described [23-25]. NRM included
all deaths without relapse or progression of the underlying malignancies.
Statistical Analysis
Theproportion of patients engraftingwas analyzed by the chi-square test.
Among engrafted patients, time to engraftment was analyzed using linearTable 2
Characteristics of Recipients of Allogeneic Hematopoietic Cell Transplantation afte
Related Donor <60 yr (n ¼ 104)
Patient age, yr
<50 33 (32%)*
50 71 (68%)
Patient sex
Female 40 (38%)
Male 64 (62%)
Ideal body weight
Data available, n 97
Median (range), kg 71 (46-86)y
Donor
Related 104 (100%)
Unrelated 0
Recipient/donor CMV status
e/e 33 (32%)*
e/þ 19 (18%)
þ/e 26 (25%)
þ/þ 26 (25%)y
Missing 0
CD34þ cell dose
Data available, n 101
Median (range), cells/kg  106 10.1 (2.4-33.7)*
Transplantation year
1999-2000 32 (31%)
2001-2002 20 (19%)
2003-2005 24 (23%)
2006-2009 28 (27%)
Diagnosis
AML 26 (25%)*
MDS 8 (8%)*
CML 5 (5%)
ALL 2 (2%)
CLL/HL/NHL 39 (38%)
Other 24 (23%)y
Median follow-up, mo 49
HCT-CI scores (% of patients)
0 22
1-2 30
3þ 48
HCT-CI indicates hematopoietic cell transplantationespeciﬁc comorbidity index.
Data presented are n (%) unless otherwise indicated.
The oldest donor was 83 years of age.
y P < .05 versus older donor group.
* P < .001 versus older donor group.regression. Factors considered as potential confounders of the relationship
between donor age and engraftment included donor type, patient sex, ideal
body weight (continuous), TBI (in myeloablative patients), CD34þ cell dose
(continuous), and patient and donor cytomegalovirus serostatus. Compari-
sons of patient characteristics were performed using the chi-square test for
categorical variables andWilcoxon rank-sum test for continuous variables.
Donor chimerism data were summarized by choosing, for each patient,
the value closest to the day of interest within7-daywindows (for example,
data for “day þ28” was collected between day þ21 and day þ35).
Cumulative incidences of acute and chronic GVHD and NRM were
estimated by standard methods. Death was a competing risk for GVHD, and
relapse or progression was a competing risk for NRM. Differences according
to donor age were assessed using Cox regression. Models were adjusted for
donor relation, patient age (continuous), TBI (in myeloablative patients),
CD34þ cell dose (continuous), female donor to male recipient, and patient
and donor cytomegalovirus serostatus. In assessment of NRM, only patients
50 years and older were included, because of the correlation of patient and
donor age among related donors.
All reported P values are 2-sided, and no adjustments were made for
multiple comparisons. Statistical analyses were performed using SAS (SAS
Institute Inc., Cary, NC).
RESULTS
Myeloablative Conditioning
Neutrophil and platelet engraftment
The trajectories of neutrophil and platelet engraftment
according to donor age are shown in Figure 1. The percentagesr Nonmyeloablative Conditioning
Unrelated Donor <60 yr (n ¼ 198) Related Donor 60 yr (n ¼ 65)
36 (18%)y 4 (6%)
162 (82%) 61 (94%)
69 (35%) 29 (45%)
129 (65%) 36 (55%)
172 58
66 (6-88) 65 (48-85)
0 65 (100%)
198 (100%) 0
63 (32%)* 7 (11%)
15 (8%) 10 (16%)
84 (42%)* 9 (14%)
36 (18%)y 38 (59%)
0 1
196 64
7.0 (1.2-37.2) 6.7 (1.7-17.8)
15 (8%) 12 (18%)
42 (21%) 14 (22%)
60 (30%) 14 (22%)
81 (41%) 25 (38%)
83 (42%) 25 (38%)
25 (13%) 14 (22%)
10 (5%) 2 (3%)
19 (10%) 4 (6%)
43 (22%) 19 (29%)
18 (9%) 1 (2%)
35 45
21
30
49
Table 3
Multivariate Regression Analysis of Patient and Transplantation Character-
istics in Relation to Time to Engraftment*
Myeloablative Patients Neutrophils
(n ¼ 935)
Platelets (n¼ 860)
Effect, d P Effect, d P
Donor 60 yr þ1.3 .04 þ.7 .65
CD34þ cell dose, per log 2.8 <.0001 6.9 <.0001
TBI .2 .39 .7 .28
Unrelated donor .1 .79 þ1.9 .006
Male þ.2 .55 þ1.3 .11
Ideal body weight, per 10 kg þ.1 .66 .1 .65
Patient CMVþ þ.1 .72 þ.2 .75
Donor CMVþ þ.2 .48 þ.2 .72
Nonmyeloablative Patients Neutrophils
(n ¼ 317)
Platelets (n ¼ 310)
Effect, d P Effect (days) P
Donor 60 yr þ.6 .51 2.3 .14
CD34þ cell dose, per log 3.1 .01 4.0 .05
Unrelated donor þ.8 .30 3.9 .001
Male þ.4 .63 þ.8 .52
Ideal body weight, per 10 kg .2 .46 .3 .60
Patient CMVþ þ1.1 .08 þ1.1 .28
Donor CMVþ 1.1 .10 þ.5 .66
* Effect is the mean difference in time to engraftment associated with the
listed variable.
Figure 1. Median neutrophil (A) and platelet (B) counts over time for mye-
loablative patients, by donor age.
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97% among those with younger donors and 98% among those
with older donors (P ¼ .45). Among those engrafting, the
estimated mean (SE) difference in time to engraftment
among patients with older donors was þ1.7  .5 days
(P ¼ .001). In multivariate analysis (Table 3), the difference in
time to engraftment associated with older donor age was
attenuated to þ1.3  .6 days (P ¼ .04). This attenuation was
likely due in part to adjustment for CD34þ cell dose, which
was decreased in older donors (median, 7.7  106 cells/kg for
younger donors versus 5.6  106 cells/kg for older donors,
P < .0001). There were no other factors demonstrating a
relationship with time to neutrophil engraftment.
The percentages of patients achieving sustained platelet
engraftment were 88% among those with younger donors
and 92% among those with older donors (P ¼ .43). Among
those engrafting, the estimated mean differences in time to
platelet engraftment among patients with older donors
were þ.2  1.3 days (P ¼ .86) in unadjusted analysis
andþ.7 1.5 days (P¼ .65) in multivariate analysis (Table 3).
CD34þ cell dose and donor relation were also related to time
to platelet engraftment.
GVHD and NRM
Figure 2 summarizes results for acute and chronic GVHD
and NRM. The cumulative incidence of day 100 acute grade 2
to 4 GVHD was 61% for patients with HLA-matched related
donors  60 years compared with 65% among related re-
cipients with donors <60 years old (adjusted P ¼ .98) and
81% for recipients with unrelated donors <60 years old
(adjusted P ¼ .008, Figure 2A). Grade 3 to 4 acute GVHDincidences for the 3 groups of patients were 14%, 10%, and
20%, respectively (adjusted P ¼ .60 and P ¼ .24, respectively).
The cumulative 2-year incidences of chronic GVHD
among the 3 groups of patients were 62%, 52%, and 53%,
respectively (Figure 2B; adjusted P ¼ .89 and P ¼ .22,
respectively). The cumulative 5-year rates of NRM for pa-
tients aged 50 and older among the 3 groups were 30%, 31%,
and 39%, respectively (Figure 2C; adjusted P¼ .99 and P¼ .22,
respectively).Nonmyeloablative Conditioning
Neutrophil and platelet engraftment
The trajectories of neutrophil and platelet engraftment
according to donor age are shown in Figure 3. The percent-
ages of patients achieving sustained neutrophil engraftment
were 98% among those with younger donors and 100%
among those with older donors (P ¼ .25). Among those
engrafting, the estimated mean (SE) difference in time to
neutrophil engraftment among patients with older donors
was þ.2  .7 days (P ¼ .81). In multivariate analysis (Table 3)
the difference in time to engraftment associated with older
donor age was þ.6  .9 days (P ¼ .51). CD34þ cell dose was
the only factor signiﬁcantly associated with neutrophil
engraftment.
The percentages of patients achieving sustained platelet
engraftment were 96% among those with younger donors
and 95% among those with older donors (P ¼ .43). Among
those engrafting, the estimated mean differences in time to
platelet engraftment among patients with older donors
were þ.7  1.1 days (P ¼ .56) in unadjusted analysis
and 2.3  1.5 days (P ¼ .14) in multivariate analysis
(Table 3). In contrast to myeloablative patients, for patients
with nonmyeloablative conditioning, grafts from unrelated
donors were associated with earlier, rather than later,
platelet engraftment. Because all older donors were related
to the recipient, we separately analyzed the subgroup of
transplant recipients with related donors, with similar re-
sults (data not shown).
Figure 2. Acute grades 2-4 GVHD (A), chronic GVHD (B), and NRM (C) out-
comes among recipients given myeloablative conditioning. NRM outcomes are
shown among recipients aged 50 and older.
Figure 3. Median neutrophil (A) and platelet (B) counts over time for non-
myeloablative recipients, by donor age.
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Chimerism data were available at days þ28, þ56,
and þ84 after HCT for 316, 223, and 239 patients, respec-
tively. There were no signiﬁcant differences in donor CD3þ
chimerism between patients with donors ages 60 years
compared with those with younger donors (P > .90 at all
times) (Figure 4). Because all older donors were related to
their recipients, we separately analyzed the subgroup of
transplant recipients with related donors, and again found
no signiﬁcant differences in chimerism at any time ac-
cording to donor age.Development of clonal malignant disorders in donor cells
To date, no clonal malignant or nonmalignant disorders of
hematopoiesis have been seen in any of the patients.
GVHD and NRM
The cumulative incidence of day 100 grades II to IV acute
GVHD was 47% for patients with HLA-matched related do-
nors 60 years old, compared with 51% for those with
related donors <60 years old (adjusted P ¼ .52) and 74% for
those with unrelated donors <60 years old (Figure 5A,
adjusted P ¼ .01). The corresponding rates of grades 3 to 4
acute GVHD were 13%, 14%, and 16%, respectively (adjusted
P ¼ .94 and P ¼ .77, respectively).
The cumulative 2-year incidences of chronic GVHD for the
3 groups of patients were 40%, 53%, and 56%, respectively
(Figure 5B, adjusted P ¼ .83 and .53, respectively).
The corresponding 5-year cumulative incidences of NRM
among patients aged 50 and older were 24%, 21%, and 26%,
respectively (Figure 5C; adjusted P ¼ .28 and P ¼ .89,
respectively).DISCUSSION
Hematopoietic cells, like all cells, are subject to aging
mechanisms, such as telomere shortening, accumulated DNA
damage, and epigenetic modiﬁcation. In 1982, Mauch et al.
showed that bone marrow from older rats, grown in culture,
had a reduced capacity for colony-forming unit production
and self-renewal compared with marrow from younger rats
[7]. However, the impact of aging on hematopoietic stem cell
Figure 5. Acute grades 2-4 GVHD (A), chronic GVHD (B), and NRM (C) out-
comes among recipients given nonmyeloablative conditioning. NRM outcomes
are shown among recipients aged 50 years and older.
Figure 4. T cell chimerism in nonmyeloablative recipients by donor age
(black ¼ younger [<60 years old], blue ¼ older [60 years old]). Median donor
T cell chimerism is the center bar in each box; the bottom and top edges of the
boxes represent 25th and 75th percentiles; and whiskers represent the 10th
and 90th percentiles.
A.R. Rezvani et al. / Biol Blood Marrow Transplant 21 (2015) 105e112110function in vivo remains a subject of some controversy. He-
matopoietic stem cell aging is thought to be a complex,
heterogeneous, and incompletely understood process on the
basis of existing animal (mostly murine) models [8-17]. Both
cell-intrinsic and epigenetic mechanisms have been impli-
cated in stem cell aging [14]. Very recent work identiﬁed
“replication stress as a potent driver of functional decline in
aging hematopoietic (murine) stem cells” [16]. The implica-
tions are unclear for the transplantation clinician faced with
an elderly potential hematopoietic cell donor, especially
given the often discrepant results of murine studies [17].
The high turnover of the hematopoietic system places a
substantial burden on a relatively small population of stem
cells, but hematopoietic reserve is typically not exhausted
during the normal lifespan of an organism. Efforts to quantify
the excess hematopoietic reserve have relied upon stressors
such as ionizing radiation or serial transplantation to further
increase the demand on hematopoietic cells [11]. Using
competitive repopulation assays,Harrison andAstle showed in
1982 that a single HCT placed the equivalent of 3 to 7 lifetimes
of stress on the transplanted hematopoietic system in mice.
They found that hematopoietic cells could be serially trans-
planted at least 5 times before losing their ability to restore
marrow function in lethally irradiated hosts, suggesting by
extrapolation that the hematopoietic system has sufﬁcient
reserve for approximately 15 to50 lifetimes in theirmodel [12].
Only 1 study has been reported in 2001 exploring the
issue of replicative senescence in a large-animal model [13].
In this study, cohorts of 6 young (.5 years) and 6 old (8 years)
canines were exposed to repeated nonlethal courses of 100
(50) cGy TBI to cause transient pancytopenia and to stress the
hematopoietic system. There were no differences in the he-
matopoietic recovery and marrow cellularity of older dogs
compared with younger dogs after 7 courses of TBI over a
period of 1 year, and the degree of telomere shortening was
likewise equivalent. The respective telomere shortening
experienced by both cohorts of dogs after 1 year of repeated
TBI corresponded roughly to that seen in untreated dogs over
an 8-year lifespan. These results suggested that the aging
hematopoietic system retained adequate reserve to respond
to supranormal stresses and demands.
The current study compared 2 aspects of allogeneic HCT
as a function of donor age. The ﬁrst was the tempo of earlyhematopoietic recovery and the second was long-term out-
comes. As for the ﬁrst aspect, we were swayed by the canine
data [13] and some of the murine studies [12,17] and
postulated that hematopoietic cells from older donors would
respond equally well as those of younger donors when
challenged to restore host hematopoiesis. This question has
substantial clinical relevance, as the extension of allogeneic
HCT to older patients has been accompanied by an increasing
number of older (sibling) donors.
We found that advanced donor age was associated with a
minimal delay in neutrophil engraftment that was seen only
aftermyeloablative allogeneic HCT. However, this association
appeared to be driven by the lower CD34þ cell doses
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nors were siblings, we examined the possibility that donor
type (HLA-identical sibling versus HLA-matched unrelated)
might confound our analysis. The results held constant when
the analysis of neutrophil change was restricted to patients
with HLA-identical sibling donors, suggesting that the higher
proportion of HLA-identical siblings among older donors did
not compromise the validity of our ﬁndings. Donor age did
not affect platelet recovery.
In the setting of nonmyeloablative HCT, we examined
both donor Tcell chimerism and recoveries in neutrophil and
platelet counts over time as clinically relevant markers of
engraftment. We found no signiﬁcant effect of donor age on
these markers. However, as with myeloablative allogeneic
HCT, CD34þ cell dose did inﬂuence the tempo of both
neutrophil and platelet recoveries. Thus, whereas a standard
plasmapheresis yielded, on average, less CD34þ cells from an
older donor, there appeared to be no clinically relevant effect
of aging on the repopulating ability of donor cells after
myeloablative and nonmyeloablative allogeneic HCT.
Long-lived hematopoietic stem cells are targets for the
accumulation of mutagenic changes and are at risk of losing
the capacity to adequately maintain tissue homeostasis after
stress [15]. As these authors say, an extreme example of
disrupted homeostasis is the development of myeloid ma-
lignancies, which have an increased incidence in the elderly.
These considerations raised the concern that recipients of
aged stem cells would be at higher risk of developing clonal
malignant disorders, especially given the enormous stress
placed on donor cells by rebuilding hematopoiesis in the
recipient. We have found no evidence so far to support this
theoretical concern. The risk of donor-derived leukemias
among younger patients with younger donors has been
estimated to be 124 in 100,000 transplantations [26].
The second aspect of the study was to examine the impact
of donor age on overall outcomes, which is more complex
and difﬁcult to answer as recipient age-associated comor-
bidities may affect prognosis.
In the myeloablative group, recipients of HCT from donors
60 years old had similar rates of acute and chronic GVHD
and similar 5-year NRM when compared with recipients of
HCT from related donors <60 years old. When compared
with recipients of HCT from younger unrelated donors, re-
cipients of grafts from older sibling donors showed signiﬁ-
cantly less acute GVHD grades II to IV.
Among the nonmyeloablative group, recipients of HCT
from sibling donors 60 years of age showed no signiﬁcant
differences from their counterparts with younger donors,
except for a reduction in acute GVHD grades II to IV
compared with those with younger unrelated donors.
Published results on the subject vary. A 2001 National
Marrow Donor Program study reported inferior overall
survival in patients receiving allografts from donors
>45 years old [27]. French investigators identiﬁed no sig-
niﬁcant impact of donor age among patients who under-
went transplantation for acute myeloid leukemia and
myelodysplasia [28,29]. In contrast, a later analysis by the
same group found that donor age60 years had a signiﬁcant
negative impact on overall survival in patients receiving
G-PBMC allografts for hematologic malignancies [30]. A
more recent Center for International Blood and Marrow
Transplant Research analysis published in 2013 found that
outcomes were superior with HLA-identical sibling donors
50 years old compared with HLA-matched unrelated
donors <50 years old [31]Whereas uncertainties remain in the area of donor selec-
tion, our ﬁndings provide additional guidance for the trans-
plantation clinician who considers an older hematopoietic
cell donor. Advanced donor age does not appear to place the
recipient at increased risk of delayed engraftment, prolonged
neutropenia, prolonged thrombocytopenia, graft rejection, or
the development of malignant clonal disorders arising from
donor cells. Moreover, no major long-term adverse effects on
GVHD and 5-year NRM were seen with grafts from older
donors. Importantly, the risk of acute GVHD grades II to IV is
signiﬁcantly lower with older sibling donors compared with
younger HLA-matched unrelated donors. These ﬁndings may
help guide the complex task of assessing potential donors for
allogeneic HCT. Given the increasing age of both recipients
and sibling donors, additional research should explore the
safety implications of the donation process for older in-
dividuals. Similarly, because this study conﬁrms the impact of
CD34þ cell dose on engraftment, our ﬁndings might suggest
investigating approaches aimed at optimally mobilizing stem
cells for collection from older donors.
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